Developing and Introducing a Dual Prevention Pill- Oral PrEP & oral contraception for HIV and pregnancy prevention
A coalition of partners is developing a novel Dual Prevention Pill (DPP) for prevention of pregnancy and HIV acquisition in high-need countries.
In East and Southern Africa — where the DPP is initially planned for introduction — 65 percent of new HIV infections are amongst women aged 15 and over, and 16 percent of women of reproductive age have an unmet need for contraception. As the “youth bulge” results in millions of young people entering their reproductive years, it will impact efforts to end the HIV epidemic and reduce unintended pregnancies. It is critical to ensure all women have access to both contraception and HIV prevention.
How Might We Motivate Uptake of the Dual Prevention Pill? Findings from human-centered design research with potential end users, male partners, and healthcare providers
This article from Frontiers in Reproductive Health describes the results of a study to identify barriers and motivators for Dual Prevention Pill (DPP) uptake to inform the development of a DPP demand generation strategy and broader introduction efforts for Multipurpose Prevention Technologies.
Normative Guidance/Policies, Service Delivery, Vertical Transmission
Elimination of vertical transmission of HIV will require expanded access to HIV prevention strategies, such as PrEP, for pregnant and breastfeeding people. Guidance from the World Health Organization (WHO) supports provision of HIV pre-exposure prophylaxis (PrEP) to pregnant and breastfeeding people (PBFP) who are at continuing substantial risk of HIV infection. Evidence has shown that…
Dual Prevention Pill: Market Preparation and Introduction Strategy
This strategy, updated in August 2023, is intended for donors, governments, implementing partners and civil society to inform priorities and planning for DPP rollout. The strategy describes activities required to build a cohesive body of evidence and recommends an approach to DPP introduction to focus efforts. Where possible, activities will be embedded into existing programs…
Integrated Study Dashboard
This dashboard, produced under the BioPIC project, reflects all currently known activities relating to implementation research, modelling, clinical research, and landscaping for new late stage biomedical HIV PrEP options, including cabotegravir for PrEP and the dapivirine vaginal ring. To update or add any activities missing from the dashboard, or if you have questions on using…
Cost-Effectiveness of the Dual Prevention Pill for Contraception and HIV Pre-Exposure Prophylaxis
This journal article from Frontiers in Reproductive Health explored what populations and in what use cases the DPP (dual prevention pill) would be cost-effective.
Equipping Providers To Offer Novel MPTs: Developing Counseling Messages for the Dual Prevention Pill in Clinical Studies and Beyond
This journal article from Frontiers in Reproductive Health shares results from mapping counseling messages from COC and oral PrEP guidance and provider training materials. This was studied by a working group of eight HIV and FP experts.
Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction Report
This report was from the BioPIC Think Tank, Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction. As new HIV prevention products move closer to entering the market, there is an opportunity to design choice-based programs that apply lessons and successes from HIV and FP…
Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction Slides
These slides were featured at the BioPIC Think Tank, Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction. As new HIV prevention products move closer to entering the market, there is an opportunity to design choice-based programs that apply lessons and successes from HIV and…
Private Sector Delivery Strategy for the Dual Prevention Pill: Kenya and Zimbabwe
This strategy was authored by the DPP Consortium to prepare for market entry of the DPP (Dual Prevention Pill) in Kenya and Zimbabwe.
Making the Case for Joint Decision-Making in Future Multipurpose Prevention Technology (MPT) Choice: Qualitative findings on MPT attribute preferences from the CUPID study (MTN-045)
This article from the Journal of the International AIDS Society uses data from the Microbicide Trials Network 045 study in Uganda and Zimbabwe to examine (1) how couples make decisions on existing non-Multipurpose Technology (MPT) HIV and pregnancy prevention products; (2) how couples make decisions on future ideal-MPT products; and (3) how these decision-making processes…